MELISA KIEFFER: Open Payments
NPI 1770599284 · MCPHERSON, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$501 in 30 payments from 13 companies in 2025. Trend: 2023 $1,122 · 2024 $1,365 · 2025 $501
Food & beverage: $501
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 5 | $94 |
| Sumitomo Pharma America, Inc. | 5 | $78 |
| AstraZeneca Pharmaceuticals LP | 4 | $73 |
| ABBVIE INC. | 4 | $65 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| GlaxoSmithKline, LLC. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Globus Medical, Inc. | 1 | $16 |
Products named: GEMTESA, PREVNAR 20, AIRSUPRA, QULIPTA, CAPLYTA, VOQUEZNA, SHINGRIX, TRUMENBA.
Industry payments across KS — which companies pay providers there.
